Candel Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Candel Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-93.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 80% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +61%In 3 years sales changed by -100% while total assets changed by +61%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-86.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 81% of Healthcare companies in United States.
Cash Cushion Ratio
+11%Cash, after subtracting all debt, equals 11% of its market value (net cash).
Higher than 52% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Candel Therapeutics, Inc. made a loss over the last year. Candel Therapeutics, Inc. owes $0.39 for every $1 it owns. Candel Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCandel Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.08The share price is 5.08 times Candel Therapeutics, Inc.'s book value per share, higher than 72% of Healthcare companies in United States.
Market cap
$641 MThe total market value of all of Candel Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 58% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$126 MWhat Candel Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.65Net worth divided by the number of shares. The share price of $8.38 is 5.1 times this, which is the P/B above.
Return on equity (ROE)
-81.8%Candel Therapeutics, Inc. lost 81.8% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
Owes vs Owns
0.39×Candel Therapeutics, Inc. owes $0.39 for every $1 it owns (low), lower than 52% of Healthcare companies in United States.
Dividend yield
NoneCandel Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossCandel Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredCandel Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCandel Therapeutics, Inc. held $71 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Candel Therapeutics, Inc.: $641 M ÷ $126 M (30 Jun 2026) = 5.1.
What is Candel Therapeutics, Inc.'s return on equity?
Candel Therapeutics, Inc. lost 81.8% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
How much does Candel Therapeutics, Inc. owe compared with what it owns?
Candel Therapeutics, Inc. owes $0.39 for every $1 it owns (low), lower than 52% of Healthcare companies in United States.
Does Candel Therapeutics, Inc. pay a dividend?
No. Candel Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.